Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bourbon Industry May Pay for Trump's Proposed Steel Tariff
The largely Kentucky-based industry could fall victim to trade wars
By Gina Carey, Newser Staff
Posted Jul 9, 2017 3:04 PM CDT
(Newser) – The EU is eyeing a potential target to use in retaliation against President Trump’s proposed steel import tariff: the US bourbon industry. Per the Guardian, commission president Jean-Claude Juncker said the EU would “react with counter-measures” within days against US agricultural exports should Trump impose import tariffs on Chinese and German steel. The US bourbon industry was specifically called out, and for good reason: 20% of the US’s $654 million spirit exports to the EU last year came from bourbon whiskey sales. At the G20 summit Friday, Juncker added that he hoped the EU could avoid such retaliatory measures, but said "we are in an elevated battle mood.” The bourbon industry is largely based in Kentucky, but WEKU reports that the pinch such taxes could bring will be felt much further.
“Anything, not just trade, but anything that impacts Kentucky bourbon affects a lot of different spin-off industries,” says Kentucky Distillers’ Association president Eric Gregory. Nearly all bourbon produced in the US (95%) comes from Kentucky in an industry that employs over 17,000. The Guardian reports that Trump won nearly 63% of the vote there in the election (not to mention it’s home turf to Senate Majority Leader Mitch McConnell). “This is a really important industry to Kentucky, so people will not be happy that this in the air,” says Susan Reigler, president of the Bourbon Women Association. Bourbon can only be produced in the US (as tequila is only made in Mexico, or champagne in France), and Gregory vows to "promote, protect, and elevate its success around the world."
in NYC. "September 7, 2017 at 9:00 a.m. (Eastern Time), at the offices of Gracin & Marlow, LLP, The Chrysler Building, 405 Lexington Avenue, 26th Floor, New York, New York 10174"
lol
And offered by Caskers:
Jefferson’s Pritchard Hill Cabernet Cask Finished
A truly distinct, tri-whiskey, Kentucky Straight bourbon blend, finished for a year in ex-Cabernet Sauvignon Chappellet Wine French Oak Casks.
$74.99
The principal author of the Declaration of Independence and one of the greatest Founding Fathers, Thomas Jefferson was elected the third President of the United States in 1800. During his tenure, Jefferson authorized the purchase of the Louisiana Territory, dispatched Lewis and Clark westward in order to explore the remainder of the continent and repealed the Whisky Excise Tax.
After Jefferson retired from public office in 1815, he often tended to the garden that he had cultivated on his Monticello estate. At the time, it was customary for wealthy farmers, including Jefferson, to distill the excess grains they harvested from their farms into spirits (George Washington was one of the country’s largest distillers of rye whiskey). As a result, each farmer’s spirits were unique and reflected the local terroir of their farm. The Jefferson’s brand pays homage to Jefferson and the exquisite whiskey he distilled.
Jefferson's Bourbon is a blender and bottler of spirits. Launched in 1997 by Trey and his father Chet Zoeller, a bourbon historian. First released in 1997, Jefferson’s has several offerings in their lineup, and utilizes very innovative and experimental blending and aging techniques. For example, their Jefferson’s Ocean expression is a bourbon, aged on a ship at sea, exposed to extreme weather conditions, crafting a truly distinct spirit.
As Jefferson Bourbon’s Master Distiller, Trey Zoeller is an aficionado of the Upper Valley Cabernet Sauvignon wines from the Pritchard Hill region of California. For their limited edition Jefferson’s Pritchard Hill, Trey collaborated with Cyril Chappellet of the Chappellet Estate Winery, using their wine casks to age the special bourbon expression.
This Jeffersons Pritchard Hill release is aged using quite a unique maturation technique; a twin wood aging process, that incorporates a blend of three complex, elegant bourbons that have been aged for one year in new American Oak barrels, and finished in ex-Pritchard Hill Cabernet Sauvignon French Oak casks. The special casks were once situated at the highly elevated, rocky slopes of the Chappellet Vineyard in St. Helena, Napa Valley. “The wine barrels that matured the most sought-after wine in the Chappellet portfolio lend a sweetness to the bourbon by adding notes of dark berry, espresso, and chocolate” (Jefferson’s).
Try this truly distinct Cabernet finished bourbon today!
Vote has to be in by July 17th. For shareholders with a record date of June 6th.
Prurisol, if approved and if it has a superior safety and efficacy profile to the drugs presently on the market would quickly begin to be prescribed by all dermatologists who keep up with developments in the field. Nonetheless, a BP would also begin marketing it to try to capture market share as rapidly as possible.
Yes, I was in IDCC. Made some money there but got out too late for one peak and too early for another. I thought MARA was the real deal with managers whose interests were more closely aligned with mine than the slugs at IDCC. Fool that I am.
DM, It is sad. I had such high hopes for MARA, as did most longs.
Agreed.
If Trey were to offer me a drink from a "regular" Jefferson's bottle, methinks I would say yes without hesitation.
Yup, the longer an entity waits to add $ROX to their fold, the higher the price. Just a question of when.
Watching with some interest but no sense of urgency. We will get our ultimate $4-5 in the next couple years. Perhaps more.
This is a long game for me. Not trading in and out, as a large entity could decide to pull the trigger at any time.
You guys can go out and mow. I'll stay in with my Jefferson's.
Time to wake up from your dream and catch that plane! Safe trip.
Thank you for the abstract Boo. Great stuff.
New positive article
https://www.insiderfinancial.com/innovation-p...ny/124462/
None of the charts or tables come thru below. The publisher deserves the clicks.
Quote:
Innovation Pharmaceuticals Inc (OTCMKTS:IPIX): New Name, Same Great Company
By Jarrod Wesson / in Biotech, Momentum Stocks, Stocks / on Thursday, 15 Jun 2017 12:55 PM / 0 Comment / 89 views
Innovation Pharmaceuticals Inc (OTCMKTS:IPIX), the biopharmaceutical company, executed a ticker change from Cellceutix Corp (OTCMKTS:CTIX). The change went into effect on June 9, 2017. As expected, the event did not have any market reaction, because the company’s assets and R&D activities remain the same. In this piece, we use the opportunity to review the stock catalysts, and the most recent developments of the company. First of all have a look at the long term price action.
Source
Business
CTIX has three drug candidates; Prurisol, Kevetrin and Brilacidin. The first drug focuses on the treatment of Psoriasis, Kevetrin is intended to combat Ovarian Carcinomas, which is a type of cancer, whereas Brilacidin is being tested for the treatment of Inflammatory Bowel Disease, and Oral Mucositis. This image will help readers understand the illnesses targeted.
CLICK TO VIEW LARGER IMAGE
Honestly, this is quite a wide spectrum of diseases, thus we will try to focus only on the drugs approved or almost approved by the FDA. The most important developments are the following ones:
Name change and Catalysts
On June 9, 2017, the company changed its name to Innovation Pharmaceuticals, Inc., and started to trade with the ticker “IPIX”. The market did not respond to the change, as day traders understood that the company and catalysts remain the same. Have a look at what happened in the last month.
Source
The share price was moved by other announcements; mainly new data released in May 30, and most importantly the information put out on May 18, 2017:
On May 30, 2017, the company disclosed new data, supporting the use of a new molecule compound of Kevetrin, for the treatment of Acute Myeloid Leukemia (AML). The company will present the findings in a poster at the 2017 European Hematology Association (EHA) Annual Meeting to be held on June 22-25 in Madrid, Spain. Readers can find the information that will be exposed here.
The most relevant information was published some weeks ago. On May 18, 2017, the company noted the completion of the third and final cohort of its Phase 2 open-label trial for the treatment of Inflammatory Bowel Disease (IBD). The drug Brilacidin was said to show “strong signs of efficacy while being well-tolerated, reinforcing its potential to become a novel, non-corticosteroid, non-biologic anti-inflammatory drug candidate“. The final trial will be limited to five patients, and the data will be presented on schedule for presentation at the Drug Discovery & Therapy World Congress in July. This is the catalyst that we were looking for. President and Chief Medical Officer, Arthur P. Bertolino, explained it in the following way:
“We expect that a complete body of data and evidence, including importantly endoscopic evaluation, will demonstrate just how safe and effective Brilacidin, as an emerging treatment, might one day become for those suffering from a wide range of debilitating inflammatory bowel conditions” Source
Social Media
Social media exploded as day traders expected a large move to happen as a result of the Phase 2 trial numbers release. Email subscribers should check the Yahoo Finance Forum and the iHub forum. Even short sellers were stated to fear the news and decided to put out a bad article about IPIX (Seeking Alpha author Mako Reseach).
Conclusion
Innovation Pharmaceuticals, Inc. received a new name and ticker, but nobody made a move, as the company remains the same. Furthermore, the announcement of a poster in the 2017 European Hematology Association (EHA) Annual Meeting to be held on June 22-25 in Madrid, Spain, was not relevant either, as the company did not have any relevant discovery to merit a publication or a presentation. Conversely, the press release put out on May 18, 2017 did make the share price move. In July, very important results will be put out about the company’s drug ‘Brilacidin’. Thus, email subscribers need to remain alert. Try to read our coverage on this stock in order to be prepared and to understand the next press release rapidly.
The increase in inventory allows for a commensurate increase in sales in following years. Some of course has to be aged. Some, like the ginger beer, can just fly out of the warehouses or more likely directly from the production plants.
Well, I like the nice increase in sales/cases but would have preferred even a one cent black number for earnings. Clearly, they have worked thru much of their supply issue. I don't think this report includes any of the Wal-Mart sales (if it does, it isn't much) and certainly the consolidation of sales and earnings, once they hit 80 pct ownership of the Goslings partnership would not be included here. Next report will allow counting all the sales and earnings.
You'll tell me if I'm wrong, but I don't think the consolidation works retroactively. Of course it was 49 years ago I last took accounting. lol
Good, glad you are back in the fold. Lets hope we all do well.
Meister, You've never been at such a loss for words before!
jS, that looks super. How many cases did you order?
Might be the endoscopic pix from our B-UP study, lol
It will be interesting to watch. Hoping this ends up nicely for us long-term longs.
And they should take the Goslings sunset rum cruise!
Sounds great to me.
$oldier, Ours will come in as profitable.
What is "high rye" bourbon:
https://bourbonveach.com/2017/06/05/what-is-high-rye-bourbon/
And remember when we were thrilled when it broke what used to be our average of 200k shares?
Someone is accumulating shares. Given that: (1) Rox has made it known that they are on the market at the "right" price; (2) one of the majors just made an abortive run at another beverage maker/seller; it may be logical to assume (3) that Rox might be a desirable addition soon for any major desiring to expand thru other than just organic growth.
ROX would be a nice "bolt-on" acquisition.
57 million shares held by insiders. Almost as many shares as we have.... lol
Heavy volume and upward price movement = good for us longs
GLTAL
Hoisting a glass of Jefferson's to those who served, those who gave their lives in our country's service and those families who brought up the service members.
Heavy rain here, on and off, on the east coast. Our BBQ will be indoors today. I have more Jefferson's to go around.
Michael Veach on Bourbon "Rectifiers"
https://bourbonveach.com/2016/05/16/history-of-rectifiers-or-non-distilling-producers/
I try!
BioVie Announces Issuance of US Patent Covering BIV201 for the Treatment of Ascites Due to Liver Cirrhosis
BEVERLY, MA--(Marketwired - May 24, 2017) - BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today announced that the US Patent and Trademark Office (USPTO) has issued US Patent No. 9,655,945 covering the Company's new drug candidate BIV201 in development for the treatment of ascites in patients with advanced liver cirrhosis.
BioVie's medical advisor Paolo Angeli, MD, and Company personnel pioneered this potential new therapeutic approach. The patent is supported by clinical data generated by Dr. Angeli and licensed exclusively to the Company by the University of Padova, Italy. It is assigned to BioVie and will provide patent exclusivity in the US under the issued claims through 2036.
"Dr. Angeli is deeply committed to improving medical therapy for these desperately ill patients and it has been our privilege to work with him," commented Jonathan Adams, BioVie CEO. "This newly-issued patent provides strong intellectual property protection for our lead therapeutic candidate BIV201. It positions BioVie as the emerging leader in developing a new drug therapy for ascites and potentially other deadly complications of advanced liver cirrhosis." BIV201 could become the first drug ever approved by the FDA for treating refractory ascites due to liver cirrhosis, a life-threatening condition which affects about 10,000 Americans.
BIV201, which has Orphan drug status, is a continuous infusion of the peptide terlipressin. It will soon commence a Phase 2a trial in 6 patients with liver cirrhosis and ascites who are refractory to, or intolerant of, diuretic therapy and require large-volume paracentesis (withdrawal of >4 liters of ascites fluid with a large-bore needle). Terlipressin, dosed differently, is approved in about 40 countries for other complications of liver cirrhosis arising from a similar disease pathway. Terlipressin is not available in the US and currently there are no drugs approved by the FDA specifically to treat ascites.
US Patent No. 9,655,945 may be viewed on the USPTO website. More information about the Company's planned Phase 2a clinical trial may be found at clinicaltrials.gov. For more information about BioVie and BIV201, please visit our website: www.biovieinc.com.
About BioVie Inc.
BioVie Inc. is a clinical-stage company pursuing the discovery, development, and commercialization of innovative drug therapies. The Company is currently focused on developing and commercializing BIV201, a novel approach to the treatment of ascites due to chronic liver cirrhosis. In March 2017, BioVie received notification from the FDA that it could initiate a Phase 2a US clinical trial. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and alcoholism. It has Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. The FDA has never approved any drug specifically for treating ascites.
About Liver Cirrhosis and Ascites
More than 600,000 Americans and millions worldwide suffer from liver cirrhosis. Cirrhosis is the 12th-leading cause of death due to disease in the US, killing an estimated 40,000 people each year. The condition results primarily from hepatitis, alcoholism, and nonalcoholic steatohepatitis (NASH) linked to fatty liver disease and obesity. Ascites is a common complication of advanced liver cirrhosis. With no medications approved by the FDA specifically for treating ascites, an estimated 40% of patients die within two years of diagnosis. Certain drugs approved for other uses may provide initial relief, but patients often fail to respond to them as ascites worsens. In addition to patient suffering, US treatment costs for liver cirrhosis, including ascites and other complications, are estimated at more than $4 billion annually.
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause BioVie's actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. BioVie has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are BioVie's need for, and the availability of, substantial capital in the future to fund its operations and research and development; and the risks that BioVie's compounds may experience delays or difficulties in commencing or completing clinical studies, may not successfully complete pre-clinical or clinical testing, or may not be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in BioVie's filings with the Securities and Exchange Commission under its former name. In addition to the risks described above and in BioVie's filings with the SEC, other unknown or unpredictable factors also could affect BioVie's results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on any forward-looking statements. BioVie undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation. BioVie cannot guarantee the completion or success of its planned Phase 2a clinical trial.
CONTACT INFORMATION:
BioVie Inc.
info@biovieinc.com
Welcome back Pete. I communicate with Lisa periodically and have not heard that she had scaled back in. Will ask.
I wonder what the exercise price will be on the options he gives up. Probably the shortest expiration ones with the highest exercise price.
Agree. Glad he posted this.
We'll also see eventually how Doug acts in executing his "heartfelt" mea culpa.
I think he was a junior guy calling for the analyst. Agreed he was not prepared.